Mycophenolate mofetil is associated with comparable treatment outcomes to methotrexate among patients with juvenile localized scleroderma.

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...